We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Diuretics Best Choice for Treating Hypertension

By HospiMedica staff writers
Posted on 13 Jan 2003
A long-term, multicenter trial that compared diuretics with calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors for lowering blood pressure has shown that diuretics are superior. More...
The results were reported in the December 18, 2002, issue of The Journal of the American Medical Association (JAMA).

The trial also included a cholesterol-lowering study that compared the effects of a statin drug with "usual care.” The difference in cholesterol levels was too small to show a difference in death rates and demonstrated only a nonsignificant decrease in the rate of heart attacks and strokes in the statin group. An arm of the trial included study of an alpha-adrenergic blocker but was stopped because those on the drug had 25% more cardiovascular events and were twice as likely to be hospitalized for heart failure than users of diuretics.

After about five years of follow-up, patients on the calcium channel blocker had 1 mm Hg higher systolic blood pressure and a 38% higher risk of developing heart failure than those taking diuretics. Patients taking ACE inhibitors had 2 mm Hg higher systolic blood pressure, a 15% higher risk of stroke, and a 19% higher risk of developing heart failure.
The study involved more than 42,000 participants with hypertension and at least one other risk factor for heart disease.

The researchers say patients now taking one of the newer medications for hypertension should talk to their doctor. "The new findings will allow doctors to achieve better blood pressure control and, more importantly, better cardiovascular health for their patients. And, they will do this at a more affordable price for their patient,” said Dr. Jeffrey Cutler, senior advisor at the US National Heart, Lung, and Blood Institute (NHLBI) which conducted the trial.




Related Links:
US National Heart, Lung, and Blood Inst.

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.